ArticleAntimicrobial agents and chemotherapy2020
Assessment of Clofazimine and TB47 Combination Activity against Mycobacterium abscessus Using a Bioluminescent Approach.
Open access · greenAbstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Identification and characterization ofMicrobiology spectrum · 2026Article
- Assessment of TB47 as a potential novel therapeutic agent:Antimicrobial agents and chemotherapy · 2025Article
- Mutations in ClpC1 or ClpX subunit of caseinolytic protease confer resistance to ilamycins in mycobacteria.Communications biology · 2025Article
- Evaluation of the In Vitro Activity of Bedaquiline, Delamanid, and Clofazimine AgainstPathogens (Basel, Switzerland) · 2025Article
- GrcC1 mediates low-level resistance to multiple drugs inMicrobiology spectrum · 2025Article
- The geneAntimicrobial agents and chemotherapy · 2025Article
- EmbB and EmbC regulate the sensitivity ofmLife · 2024Article
- Assessment of the Efficacy of the Antihistamine Drug Rupatadine Used Alone or in Combination against Mycobacteria.Pharmaceutics · 2024Article
- Clofazimine as a comparator for preclinical efficacy evaluations of experimental therapeutics against pulmonary M. abscessus infection in mice.Tuberculosis (Edinburgh, Scotland) · 2022Article
- Arabinosyltransferase C Mediates Multiple Drugs Intrinsic Resistance by Altering Cell Envelope Permeability in Mycobacterium abscessus.Microbiology spectrum · 2022Article
- Potency of Omadacycline against Mycobacteroides abscessus Clinical IsolatesAntimicrobial agents and chemotherapy · 2022Article
- Uncovering interactions between mycobacterial respiratory complexes to target drug-resistantFrontiers in cellular and infection microbiology · 2022Review
- The QcrB Inhibitors TB47 and Telacebec Do Not Potentiate the Activity of Clofazimine in Mycobacterium abscessus.Antimicrobial agents and chemotherapy · 2021Article
- Sterilizing Effects of Novel Regimens Containing TB47, Clofazimine, and Linezolid in a Murine Model of Tuberculosis.Antimicrobial agents and chemotherapy · 2021Article
- Nitric Oxide-Dependent Electron Transport Chain Inhibition by the CytochromeAntimicrobial agents and chemotherapy · 2021Article
- Ultra-short-course and intermittent TB47-containing oral regimens produce stable cure against Buruli ulcer in a murine model and prevent the emergence of resistance forActa pharmaceutica Sinica. B · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 3 countries.
Yang Liu *State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Yaoju Tan *State Key Laboratory of Respiratory Disease, Department of Clinical Laboratory, Guangzhou Chest Hospital, Guangzhou, China.
M Mahmudul Islam *State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Yuanyuan Cao *State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Xiaoyun Lu *School of Pharmacy, Jinan University, Guangzhou, China.
Sheng ZengState Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
H M Adnan HameedState Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Peipei ZhouState Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Xingshan CaiState Key Laboratory of Respiratory Disease, Department of Clinical Laboratory, Guangzhou Chest Hospital, Guangzhou, China.
Shuai WangState Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Julius N MugweruState Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Guoliang ZhangGuangdong Key Laboratory of Emerging Infectious Diseases, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, China.
Huancai YinChinese Academy of Sciences Key Laboratory of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Jiangsu, China.
Jianxiong LiuState Key Laboratory of Respiratory Disease, Department of Clinical Laboratory, Guangzhou Chest Hospital, Guangzhou, China.
Eric NuermbergerCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Tianyu ZhangState Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China zhang_tianyu@gibh.ac.cn.ORCID 0000-0001-5647-6014
Chinese Academy of Sciences · CNState Key Laboratory of Respiratory Disease · CNJinan University · CNJohns Hopkins University · USSouthern University of Science and Technology · CN
Funding
Exploiting a robust drug discovery portfolio to develop effective regimens to treat Mycobacterium abscessus lung infectionR21AI137814 · NIAID · JOHNS HOPKINS UNIVERSITY · PI NUERMBERGER, ERIC L · 2018 to 2019
$450kNIAID NIH HHS R21 AI137814
Abstract
PubMed holds no abstract for this paper.
Indexed as
AmikacinAnimalsAnti-Bacterial AgentsBacterial ProteinsClarithromycinClofazimineDrug CombinationsDrug Resistance, Multiple, BacterialDrug SynergismElectron TransportElectron Transport Complex IIIEnzyme InhibitorsFemaleGenetic EngineeringLuminescenceMiceAmikacinAnti-Bacterial AgentsBacterial ProteinsClarithromycinClofazimineDrug CombinationsElectron Transport Complex IIIEnzyme InhibitorsRecombinasesRoxithromycinautoluminescentclofaziminecytochrome bc1 inhibitorMycobacterium abscessusTB47
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.